@article{ATM16419,
author = {Kah Weng Lau and Claudia Seng and Tony K. H. Lim and Daniel S. W. Tan},
title = {Expanded molecular interrogation for potential actionable targets in non-squamous non-small cell lung cancer},
journal = {Annals of Translational Medicine},
volume = {5},
number = {18},
year = {2017},
keywords = {},
abstract = {The advent of targeted therapies has established new standards of care for defined molecular subsets of non-small cell lung cancer (NSCLC). Not only has this led to significant changes in the routine clinical management of lung cancer e.g. multiplexed genomic testing, but it has provided important principles and benchmarks for determining “actionability”. At present, the clinical paradigms are most evolved for EGFR mutations and ALK rearrangements, where multiple randomized phase III trials have determined optimal treatment strategies in both treatment naïve and resistant settings. However, this may not always be feasible with low prevalence alterations e.g., ROS1 and BRAF mutations. Another emerging observation is that not all targets are equally “actionable”, necessitating a rigorous preclinical, clinical and translational framework to prosecute new targets and drug candidates. In this review, we will cover the role of targeted therapies for NSCLC harbouring BRAF, MET, HER2 and RET alterations, all of which have shown promise in non-squamous non-small cell lung cancer (ns-NSCLC). We further review some early epigenetic targets in NSCLC, an area of emerging interest. With increased molecular segmentation of lung cancer, we discuss the upcoming challenges in drug development and implementation of precision oncology approaches, especially in light of the complex and rapidly evolving therapeutic landscape.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/16419}
}